Immediate Impact

18 standout
Sub-graph 1 of 7

Citing Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines
2025 Standout
15 intermediate papers

Works of Agathe Ceppe being referenced

Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis
2023
A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes
2020
and 11 more

Author Peers

Author Last Decade Papers Cites
Agathe Ceppe 318 18 37 68 65 35 514
Jacques A. Pralong 257 11 38 14 43 26 649
Gerald Ullrich 414 116 4 37 24 32 602
Gail Stewart 96 6 4 36 47 31 619
Michael McDermott 114 6 9 19 35 34 531
Dara Brodsky 162 11 57 42 29 647
Oisin O’Connell 301 11 11 117 75 24 479
Hamed Habib 123 21 4 27 25 30 542
Sally Wilson 72 3 10 137 63 36 549
Lars Bruun Larsen 109 15 11 27 59 44 572
Takashi Motegi 388 12 3 108 162 45 637

All Works

Loading papers...

Rankless by CCL
2026